EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

04 September 2024
EMA/385873/2024
EMEA/H/C/005169

Public statement

Nyxthracis[1] (obiltoxaximab)

Withdrawal of the marketing authorisation in the European Union

On 2 August 2024 the European Commission withdrew the marketing authorisation under exceptional circumstances for Nyxthracis (obiltoxaximab) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, SFL Pharmaceuticals Deutschland GmbH, which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Nyxthracis was granted marketing authorisation under exceptional circumstances in the EU on 18 November 2020 for treatment of inhalational anthrax due to *Bacillus anthracis*, in combination with appropriate antibacterial drugs, and for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available. The medicinal product was subject to annual re-assessment of the marketing authorisation under exceptional circumstances.

The European Public Assessment Report (EPAR) for Nyxthracis will be updated to indicate that the marketing authorisation is no longer valid.

[1] Previously known as Obiltoxaximab SFL

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union

© European Medicines Agency, 2024. Reproduction is authorised provided the source is acknowledged.